From Electronic Noses to Agentic Drug Design: What Cancer AI Looks Like Now

Over roughly the past year, artificial intelligence in oncology has spread well beyond scan reading and pathology support. New systems are being used to infer molecular states from tissue images, design tumor-sensitive sensors, narrow patient subgroups for trials, and support multi-step research workflows. A part of oncology now looks like a broader attempt to treat cancer as a data problem across detection, treatment planning, and drug development.

This is a condensed version of our deep dive that looks at what has actually shipped into experiments and pipelines so far, which projects have real validation behind them, and why oncology has become a natural testbed for these AI systems.

Cancer as a Data Problem: What AI Is Doing in Oncology

Why cancer became a data problem

Cancer has become a productive target for AI in part because oncology already produces the kind of layered data machine learning systems can use. A tumor is not a static but an evolving population of cells accumulating mutations, signaling to neighbors, adapting to treatment, and interacting with the immune system. 

Capturing that behavior means working across many data types at once like pathology, radiology, sequencing, spatial biology, treatment history, and clinical outcomes.

That data base is now large enough to support increasingly ambitious models. The Cancer Genome Atlas alone contains around 2.5 petabytes of raw data and has become one of the foundational resources of modern oncology research. What's changing now is how groups are starting to connect those layers.

One recent example comes from Noetik in non-small cell lung cancer. The company has assembled a spatial multi-omics atlas of more than 1,000 cases, combining protein mapping, H&E images, spatial transcriptomics, and exome sequencing. Around 10% of these samples are linked to real clinical outcomes, which is used to train its transformer engine, OCTO, to suggest which drugs are likely to work for which patients.

That kind of dataset is useful not only because it is so large, but because it begins to connect tumor biology, phenotype, and treatment response in one framework.